公开(公告)号：US09132124B2

公开(公告)日：2015-09-15

申请号：US13476883

申请日：2012-05-21

申请人： Mehdi Paborji ,  Wendy Jade Limayo Hernandez ,  Kenneth L. Duchin ,  Roger S. Flugel

发明人： Mehdi Paborji ,  Wendy Jade Limayo Hernandez ,  Kenneth L. Duchin ,  Roger S. Flugel

IPC分类号： A61K31/4178 ,  A61K31/4725

CPC分类号： A61K31/4178 ,  A61K31/4725 ,  A61K2300/00

摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

摘要翻译： 本文公开了包含治疗有效量的延长释放索非那新或其药学上可接受的盐和治疗有效量的毛果芸香碱或其药学上可接受的盐的药物组合物。 本文还公开了治疗患有膀胱过度活动症的患者的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放索非那新或其药学上可接受的盐和治疗有效量 毛果芸香碱或其药学上可接受的盐。 本文还公开了减轻患有其中的患者的膀胱过度活动症的副作用的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放索非那新或其药学上可接受的盐 以及治疗有效量的毛果芸香碱或其药学上可接受的盐。

公开(公告)号：US20120289567A1

公开(公告)日：2012-11-15

申请号：US13476901

申请日：2012-05-21

申请人： Mehdi PABORJI ,  Kenneth L. DUCHIN ,  Wendy Jade Limayo HERNANDEZ ,  Roger S. FLUGEL

发明人： Mehdi PABORJI ,  Kenneth L. DUCHIN ,  Wendy Jade Limayo HERNANDEZ ,  Roger S. FLUGEL

IPC分类号： A61K31/4178 ,  A61P13/10

CPC分类号： A61K31/4025 ,  A61K31/4178 ,  A61K2300/00

摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release darifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20120289560A1

公开(公告)日：2012-11-15

申请号：US13467177

申请日：2012-05-09

申请人： Mehdi PABORJI ,  Kenneth L. DUCHIN ,  Wendy Jade Limayo HERNANDEZ ,  Roger S. FLUGEL

发明人： Mehdi PABORJI ,  Kenneth L. DUCHIN ,  Wendy Jade Limayo HERNANDEZ ,  Roger S. FLUGEL

IPC分类号： A61K31/4178 ,  A61P13/10

CPC分类号： A61K31/137 ,  A61K31/4178 ,  A61K2300/00

摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

摘要翻译： 本文公开了包含治疗有效量的延长释放托特罗定或其药学上可接受的盐和治疗有效量的毛果芸香碱或其药学上可接受的盐的药物组合物。 本文还公开了治疗患有膀胱过度活动症的患者的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放托非罗定或其药学上可接受的盐和治疗有效量 毛果芸香碱或其药学上可接受的盐。 本文还公开了减轻患有其中的患者的膀胱过度活动症的副作用的方法，该方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放托特罗定或其药学上可接受的盐 以及治疗有效量的毛果芸香碱或其药学上可接受的盐。

公开(公告)号：US06936583B2

公开(公告)日：2005-08-30

申请号：US10794383

申请日：2004-03-05

申请人： Samuel Broder ,  Kenneth L. Duchin ,  Sami Selim

发明人： Samuel Broder ,  Kenneth L. Duchin ,  Sami Selim

IPC分类号： A61K31/337 ,  A61K38/13 ,  A61K45/06 ,  A61K38/00 ,  A61K31/335

CPC分类号： A61K31/337 ,  A61K38/13 ,  A61K45/06 ,  Y02A50/411 ,  A61K2300/00

摘要： Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.

摘要翻译： 迄今为止表现出差或不存在的口服生物利用度的紫杉烷抗肿瘤药物经口给患有紫杉烷反应性疾病病症的人类患者，并且具有足够的生物利用度以达到治疗血液水平。 在一个优选的实施方案中，使用口服环孢菌素增强剂（优选环孢菌素A）将紫杉烷，优选紫杉醇共同施用于患者。通过一种优选的方法，口服增强剂的剂量在紫杉烷和紫杉烷之前约0.5-72小时 第二剂量的增强剂，并在紫杉烷之前，之前或之后施用。 还提供了治疗患有紫杉烷反应性疾病病症的人类患者的方法，以及一种在不需要预先给药的情况下预防或减少过敏反应和过敏反应的方法。

公开(公告)号：US06395770B1

公开(公告)日：2002-05-28

申请号：US09385246

申请日：1999-08-28

申请人： Samuel Broder ,  Kenneth L. Duchin ,  Sami Selim

发明人： Samuel Broder ,  Kenneth L. Duchin ,  Sami Selim

IPC分类号： A61K31335

CPC分类号： A61K31/337 ,  A61K38/13 ,  A61K45/06 ,  Y02A50/411 ,  A61K2300/00

摘要： Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxaneresponsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.

摘要翻译： 迄今为止表现出差或不存在的口服生物利用度的紫杉烷抗肿瘤药物经口给患有紫杉烷反应性疾病病症的人类患者，并且具有足够的生物利用度以达到治疗血液水平。 在一个优选的实施方案中，使用口服环孢菌素增强剂（优选环孢菌素A）将紫杉烷，优选紫杉醇共同施用于患者。通过一种优选的方法，口服增强剂的剂量在紫杉烷和紫杉烷之前约0.5-72小时 第二剂量的增强剂，并在紫杉烷之前，之前或之后施用。 还提供了治疗患有紫杉烷应答疾病病症的人类患者的方法，以及一种在不需要预先给药的情况下预防或减少过敏反应和过敏反应的方法。

公开(公告)号：US20120289566A1

公开(公告)日：2012-11-15

申请号：US13476874

申请日：2012-05-21

申请人： Mehdi PABORJI ,  Kenneth L. DUCHIN ,  Roger S. FLUGEL

发明人： Mehdi PABORJI ,  Kenneth L. DUCHIN ,  Roger S. FLUGEL

IPC分类号： A61K31/4178 ,  A61P13/00

CPC分类号： A61K31/222 ,  A61K31/4178 ,  A61K2300/00

摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

摘要翻译： 本文公开了包含治疗有效量的延长释放非索罗定或其药学上可接受的盐和治疗有效量的毛果芸香碱或其药学上可接受的盐的药物组合物。 本文还公开了治疗患有膀胱过度活动症的患者的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放非索罗定或其药学上可接受的盐和治疗有效量 毛果芸香碱或其药学上可接受的盐。 本文还公开了减轻患有其中的患者的膀胱过度活动症的副作用的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放的非索罗定或其药学上可接受的盐 以及治疗有效量的毛果芸香碱或其药学上可接受的盐。

公开(公告)号：US20120289544A1

公开(公告)日：2012-11-15

申请号：US13476883

申请日：2012-05-21

申请人： Mehdi PABORJI ,  Wendy Jade Limayo HERNANDEZ ,  Kenneth L. DUCHIN ,  Roger S. FLUGEL

发明人： Mehdi PABORJI ,  Wendy Jade Limayo HERNANDEZ ,  Kenneth L. DUCHIN ,  Roger S. FLUGEL

IPC分类号： A61K31/439 ,  A61P13/00

CPC分类号： A61K31/4178 ,  A61K31/4725 ,  A61K2300/00

摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

摘要翻译： 本文公开了包含治疗有效量的延长释放索非那新或其药学上可接受的盐和治疗有效量的毛果芸香碱或其药学上可接受的盐的药物组合物。 本文还公开了治疗患有膀胱过度活动症的患者的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放索非那新或其药学上可接受的盐和治疗有效量 毛果芸香碱或其药学上可接受的盐。 本文还公开了减轻患有其中的患者的膀胱过度活动症的副作用的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的延长释放索非那新或其药学上可接受的盐 以及治疗有效量的毛果芸香碱或其药学上可接受的盐。

公开(公告)号：US06610735B2

公开(公告)日：2003-08-26

申请号：US09829846

申请日：2001-04-10

申请人： Samuel Broder ,  Kenneth L. Duchin ,  Sami Selim

发明人： Samuel Broder ,  Kenneth L. Duchin ,  Sami Selim

IPC分类号： A61K31337

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/337 ,  A61K38/13 ,  Y02A50/411 ,  A61K2300/00

摘要： A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.

公开(公告)号：US08940763B2

公开(公告)日：2015-01-27

申请号：US13467195

申请日：2012-05-09

申请人： Mehdi Paborji ,  Wendy Jade Limayo Hernandez ,  Kenneth L. Duchin ,  Roger S. Flugel

发明人： Mehdi Paborji ,  Wendy Jade Limayo Hernandez ,  Kenneth L. Duchin ,  Roger S. Flugel

IPC分类号： A01N43/90 ,  A61K31/44 ,  A01N43/50 ,  A61K31/415 ,  C07D453/02 ,  C07D233/00 ,  A61K31/4725 ,  A61K31/4178

CPC分类号： A61K31/4178 ,  A61K31/4725 ,  A61K2300/00

摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20140194454A1

公开(公告)日：2014-07-10

申请号：US14205168

申请日：2014-03-11

申请人： Mehdi PABORJI ,  Kenneth L. DUCHIN ,  Wendy Jade Limayo HERNANDEZ ,  Roger S. FLUGEL

发明人： Mehdi PABORJI ,  Kenneth L. DUCHIN ,  Wendy Jade Limayo HERNANDEZ ,  Roger S. FLUGEL

IPC分类号： A61K31/46 ,  A61K31/4178

CPC分类号： A61K31/46 ,  A61K31/4178 ,  A61K2300/00

摘要： Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release trospium, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

摘要翻译： 本文公开了包含治疗有效量的立即释放蚤或其药学上可接受的盐和治疗有效量的毛果芸香碱或其药学上可接受的盐的药物组合物。 本文还公开了治疗患有膀胱过度活动症的患者的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的立即释放蚤或其药学上可接受的盐和治疗有效量 毛果芸香碱或其药学上可接受的盐。 本文还公开了减轻患有其中的患者的膀胱过度活动症的副作用的方法，所述方法包括鉴定有需要的患者，以及向患者施用治疗有效量的立即释放蚤或其药学上可接受的盐 以及治疗有效量的毛果芸香碱或其药学上可接受的盐。